Plasma levels of brain derived-neurotrophic factor and catecholamine metabolites are increased during active phase of psychotic symptoms in CNS lupus: a case report.
In the present study, the authors reported a case of systemic lupus erythematosus (SLE) with central nervous system involvement (CNS lupus). The authors also longitudinally investigated plasma levels of brain-derived neurotrophic factor (BDNF) and catecholamine metabolites in the patient, and found that plasma levels of BDNF, 3-methoxy-4-hydroxyphenylglycol (MHPG), and homovanillic acid (HVA) were raised in accordance with the severity of psychotic symptoms in this case of CNS lupus. These results suggest that it is useful to measure plasma levels of BDNF and the catecholamine metabolites in order to predict the severity of psychotic symptoms in CNS lupus and to provide a differential diagnosis from that of steroid-induced psychosis.
Ikenouchi
Atsuko
A
Department of Psychiatry, University of Occupational and Environmental Health, Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka 8078555, Japan.
Yoshimura
Reiji
R
Ikemura
Naomi
N
Utsunomiya
Kensuke
K
Mitoma
Masae
M
Nakamura
Jun
J
D000328:Adult; D019208:Brain-Derived Neurotrophic Factor / Q000097:blood*; D002395:Catecholamines / Q000097:blood*; D006719:Homovanillic Acid / Q000097:blood; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000379:methods; D008734:Methoxyhydroxyphenylglycol / Q000097:blood; D011618:Psychotic Disorders / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods
D019208:Brain-Derived Neurotrophic Factor; D002395:Catecholamines; D007166:Immunosuppressive Agents; D008734:Methoxyhydroxyphenylglycol; D006719:Homovanillic Acid